Ahring et al, 2016
A pharmacological assessment of agonists and modulators at α4β2γ2 and α4β2d GABAA receptors: The challenge in comparing apples with oranges. Pharmacol Res
Hartiadi et al, 2016
High and low GABA sensitivity α4β2d GABAA receptors are expressed in Xenopus laevis oocytes with divergent stoichiometries. Biochem Pharmacol 103:98-108
de Lucas et al, 2015
GABAA α5 subunit-containing receptors do not contribute to reversal of inflammatory-induced spinal sensitization as indicated by the unique selectivity profile of the GABAA receptor allosteric modulator NS16085. Biochem Pharmacol 93:370-379
Munro et al, 2009
Developing analgesics by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targets. Trends Pharmacol Sci 30:453-459
Munro et al, 2008
Comparison of the novel subtype-selective GABAA receptor-positive allosteric modulator NS11394 [3′-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile] with diazepam, zolpidem, bretazenil, and gaboxadol in rat models of inflammatory and neuropathic pain.
J Pharmacol Exp Ther 327:969-981
Ahring et al, 2015
Engineered α4β2 nicotinic acetylcholine receptors as models for measuring agonist binding and effect at the orthosteric low-affinity α4-α4 interface.
Grupe et al, 2013
Selective potentiation of (α4)3(β2)2 nicotinic acetylcholine receptors augments amplitudes of prefrontal acetylcholine- and nicotine-evoked glutamatergic transients in rats.
Biochem Pharmacol 86:1487-1496
Grupe et al, 2013
Unravelling the mechanism of action of NS9283, a positive allosteric modulator of (α4)3(β2)2 nicotinic ACh receptors.
Br J Pharmacol 68:2000-2010
Timmermann et al, 2012
Augmentation of cognitive function by NS9283, a stoichiometry-dependent positive allosteric modulator of α2- and α4-containing nicotinic acetylcholine receptors.
Br J Pharmacol 167:164-182
Harpsøe et al, 2012
Unraveling the high- and low-sensitivity agonist responses of nicotinic acetylcholine receptors.
J Neurosci 31:10759-10766
Potassium Channel field
Nguyen et al, 2017
Potassium channel expression and function in microglia: plasticity and possible species variations.
Channels (in press)
Christophersen and Wulff, 2015
Pharmacological gating modulation of small- and intermediate-conductance Ca(2+)-activated K(+) channels (Kca2.x and Kca3.1).
Grunnet et al, 2014
Kv7 channels as targets for anti-epileptic and psychiatric drug-development.
Eur J Pharmacol 726:133-137
Dolga et al, 2014
Subcellular expression and neuroprotective effects of SK channels in human dopaminergic neurons.
Cell Death and Disease 5:e999
Strøbæk et al, 2013
NS6180, a new K(Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease.
Br J Pharmacol 168:432-44